Abstract: The present invention relates to application of gossypol and its optical isomers to preparation of an anti-Coronavirus drug. Specifically disclosed is application of pharmaceutically acceptable salts, solvates, isotopes, stereoisomers, stereoisomer mixtures, and tautomers of the gossypol and its optical isomers to preparation of a drug for preventing and/or treating a disease caused by a Coronavirus. The Coronavirus is MERS-CoV, SARS-CoV, or SARS-CoV-2. It is found in the present invention for the first time that the gossypol and its optical isomers can inhibit the activity of Coronavirus 3CL proteases to achieve an anti-Coronavirus effect. The half maximal inhibitory concentrations of gossypol and (?)-gossypol to SARS-CoV proteases and SARS-CoV-2 3CL proteases are all lower than 10 ?M. The anti-Coronavirus 3CL protease effect is good. Therefore, the gossypol and its optical isomers have the potential for use in the preparation of a drug for preventing and/or treating novel Coronavirus infections.

Abstract: The present invention relates to the technical field of medicinal chemistry, and particularly to a method for preparing a 3-tetrazolylmethyl-1,3,5-triazin-2,4-dione compound inhibiting coronavirus 3CL protease activity and use thereof. Specifically, a compound of Formula I, or a pharmaceutically acceptable salt, or an optical isomer, or an isotope-substituted form thereof is provided. The compound effectively inhibits the SARS-CoV-2 3CLpro activity, and is useful in the preparation of a SARS-CoV-2 3CLpro inhibitor to block the replication and transcription of SARS-CoV-2 viruses in patients. The compound prepared in the present invention has high in-vitro safety, and very good prospect of application in the preparation of SARS-CoV-2 3CLpro inhibitors and anti-SARS-CoV-2 drugs.

Abstract: A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

Abstract: Disclosed is a compound of formula I, a pharmaceutically acceptable salt, or a tautomer thereof. formula I. R1, R2, R3 and R4 are independently selected from the group consisting of hydrogen, methyl group, tert-butyl group, methoxy group, difluoromethyl, trifluoromethyl, trifluoromethoxy, nitro, halogen, phenyl and aromatic heterocyclic; R5 is a hydrogen or halogen; and R6 is hydrogen, C1-4 alkane or C1-4 cycloalkane.

Abstract: A method of preparing a Polygoni Milletii Rhizome tincture includes: preparing a first mixture; extracting the first mixture with 70-90% ethanol under reflux condition to obtain a first extract solution; preparing a second mixture; extracting the second mixture with 50-70% ethanol to obtain a second extract solution; and mixing the first extract solution with the second extract solution to obtain the polygoni milletii rhizome tincture. A method of preparing a Polygoni Milletii Rhizome poultice includes: reparing a Polygoni Milletii Rhizome mixture; mixing the Polygoni Milletii Rhizome mixture and a skin penetration enhancer in water; mixing a moisturizing agent and a binder in water; adding a thickener in water; mixing methylparaben and ethylparaben in 90% ethanol; mixing all solutions to form a mixture; and applying the mixture on a non-woven fabric cloth and drying to form the Polygoni Milletii Rhizome poultice.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. The Linker is or and n is 1-6.

Abstract: A compound of formula I or formula II, a pharmaceutically acceptable salt, or a tautomer thereof is disclosed. In formula I and II, n is 1-6.

Abstract: A Syringa microphylla seed extract includes the following components by weight based on a total weight of the Syringa microphylla seed extract: 0.4944-0.7142 mg/g of echinacoside, 6.624-7.617 mg/g of oleuropein, 0.4276-0.6309 mg/g of verbascoside, 3.927-4.684 mg/g of syringin, and 4.505-5.250 mg/g of forsythiaside B. A method of preparing the Syringa microphylla seed extract is disclosed. A composition for treating antibiotic-resistant infections that includes the Syringa microphylla seed extract is also disclosed.

Abstract: A method for extracting herbal medicine includes: step one, spray extraction; step two, pressure filtration and concentration; step three, spray and countercurrent precipitation; and step four, concentrating reduced pressure and drying.

Abstract: A compound of Formula I: is disclosed. A method of preparing the compound of Formula I is also disclosed. R is alkyl, haloalkyl, aryl, or substituted aryl.

Abstract: A method for extracting herbal medicine includes: step one, spray extraction; step two, pressure filtration and concentration; step three, spray and countercurrent precipitation; and step four, concentrating reduced pressure and drying.

Abstract: A gossypol isatin Schiff base compound with antitumor activities represented by formula I: R1 and R2 are independently hydrogen, alkyl, cycloalkyl, alkoxy, nitro, halogen, unsubstituted or substituted phenyl, or unsubstituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.

Abstract: A gossypol 7-N-isatin Schiff base compounds compound with antitumor activities represented by formula I: is disclosed. In formula I, R is hydrogen, alkyl, cycloalkyl, alkoxy, unsubstituted or substituted phenyl, or substituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.

Abstract: A gossypol isatin Schiff base compound with antitumor activities represented by formula I: R1 and R2 are independently hydrogen, alkyl, cycloalkyl, alkoxy, nitro, halogen, unsubstituted or substituted phenyl, or unsubstituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.

Abstract: A gossypol 7-N-isatin Schiff base compounds compound with antitumor activities represented by formula I: is disclosed. In formula I, R is hydrogen, alkyl, cycloalkyl, alkoxy, unsubstituted or substituted phenyl, or substituted or substituted benzyl. A method of preparing the compound of formula I is also disclosed.

Abstract: A gossypol eflornithine Schiff base compound having the following Formula I: is disclosed. A method of preparing the compound of Formula I is also disclosed.

Abstract: A compound with antitumor activities is represented by formula I: A method of preparing the compound of formula I is also disclosed.

Abstract: A compound with antitumor activities represented by formula I: In formula I, R1 is alkyl, alkoxy, or ethenyl; and R2 is alkyl, alkoxy, or halogen.

Abstract: A compound with antitumor activities is represented by formula A or formula B R1, R2, R3, and R4 are independently hydrogen, hydroxyl, alkoxy, halogen, formyl, unsubstituted or substituted alkyl, or unsubstituted or substituted cycloalkyl.